From: Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
Wk 12
Wk 52
Control
TCZ
JIA ACR responses, n (%)
(N=37)
(N=75)
(N=88)
ACR30 = absence of fever
9 (24)
64 (85)
77 (88)
ACR70
3 (8)
53 (71)
78 (89)
ACR90
2 (5)
28 (37)
57 (65)